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Abstract
Background: Indirect comparisons are becoming increasingly popular for evaluating medical treatments that have not been
compared head-to-head in randomized clinical trials (RCTs). While indirect methods have grown in popularity and
acceptance, little is known about the fragility of confidence interval estimations and hypothesis testing relying on this
method.
Methods: We present the findings of a simulation study that examined the fragility of indirect confidence interval
estimation and hypothesis testing relying on the adjusted indirect method.
Findings: Our results suggest that, for the settings considered in this study, indirect confidence interval estimation suffers
from under-coverage while indirect hypothesis testing suffers from low power in the presence of moderate to large
between-study heterogeneity. In addition, the risk of overestimation is large when the indirect comparison of interest relies
on just one trial for one of the two direct comparisons.
Interpretation: Indirect comparisons typically suffer from low power. The risk of imprecision is increased when comparisons
are unbalanced.
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Introduction
In recent years, the adjusted indirect comparisons method, first
suggested by Bucher et al.[1], has been widely used to compare
competing treatments in the absence of direct evidence about their
relative performance.[2] For instance, if two treatments B and C
are compared against a common comparator, treatment A, via
two distinct sets of randomized trials, this method can be used to
derive an indirect estimate of the relative effect of B versus C on
the basis of the direct estimates of the relative effects of B versus A
and C versus A.
For the adjusted indirect method, it is generally well understood
that the precision of the resulting indirect estimate of the relative
effect of B versus C is lower than that of the direct estimate that
would have been obtained if direct evidence from trials comparing
B and C head-to-head were available.3 Indeed, under certain
assumptions, it has been established that an indirect estimate of B
versus C would have to be based, on average, on four times as
many trials than a direct estimate to achieve the same precision as
the direct estimate.[3] These assumptions are as follows: (i) all
within-study variances are (approximately) equal within and across
pair-wise comparisons of treatments, (ii) between-study vari-
ances are (approximately) equal across pair-wise comparisons of
treatments and (iii) each pair-wise comparison of treatments
includes an equal number of trials.
Wells et al.[4] have investigated in great detail the mean
squared error properties of the indirect point estimation of the
relative effect of B versus C by means of a simulation study.
However, to our knowledge, there have been no attempts in the
literature to expand the scope of this investigation to the study of
the risk of overestimation as well as the properties of confidence
interval estimation and hypothesis testing regarding the relative
effect of B versus C.
The power of indirect comparisons to detect differences in
treatment effects, if they exist, is a particularly important one for
clinical practice. In settings where the direct evidence available for
the comparison of B versus A is sparse relative to that available for
the comparison of C versus A, we need to understand the extent to
which the indirect comparison of B versus C may be under-
powered. Intuitively, if the direct comparison of B versus A is
under-powered, we would also expect the indirect comparison of B
versus C to be under-powered, as it relies on the direct comparison
of B versus A in addition to that of C versus A.
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16237In this paper, we present the results of a simulation study that
examines the performance of the following aspects concerning the
indirect inference on the relative effect of B versus C: (i)
overestimation associated with point estimation of the indirect
estimate of B versus C (ii) coverage of confidence intervals for the
relative effect of B versus C, (iii) type I error of tests of hypotheses
concerning the relative effect of B versus C and (iv) power of tests
of hypotheses concerning the relative effect of B versus C. Our
study focuses on effects expressed on the odds ratio scale, though it
could be easily extended to effects expressed on different scales.[4]
We start by explaining the Bucher method. We then describe
the design of our simulation study and present its results. We
conclude by discussing the practical implication of the findings of
this simulation study.
Adjusted indirect comparisons
In many situations, we are interested in assessing the relative
effects of three different treatments – A, B and C – on the basis of
randomized trials that have compared B against A and C against
A, but not B against C.
In the absence of direct evidence for the comparison of B against
C, the adjusted indirect method provides a convenient way to
conduct inferences on the relative effect of B versus C based on the
point estimates of the relative effects of B versus A and C versus A
and their associated standard errors. While these relative effects can
be expressed on any suitable way for the data produced by the trials
of B versus A and C versus A, we briefly explain below how the
methodworksforthecasewherethesedata arebinaryinnature and
the relative effects are expressed on the odds ratio scale.
Let ORAB, ORAC and ORBC represent the true relative effects
of B versus A, C versus A and B versus C, respectively. Further-
more, let log d OR ORAB
  
be the direct estimate of log ORAB ðÞ and
SE log d OR ORAB
     
be its associated estimated standard error, both
of which are obtained via standard meta-analytic methods on
the basis of the trials comparing A and B head-to-head.
Similarly, let log d OR ORAC
  
be the direct estimate of ORAC and
SE log d OR ORAC
     
be its corresponding estimated standard error,
derived on the basis of standard meta-analytic methods from the
trials comparing A and C directly.
According to the Bucher method, the indirect estimate of
log ORBC ðÞ and its accompanying standard error can be obtained as:
log d OR ORBC
  
~log d OR ORAC
  
{log d OR ORAB
  
SE log d OR ORBC
     
~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE log d OR ORAB
      2
zSE log d OR ORAC
      2
r
Combining these two pieces of information yields a 95%
confidence interval for log ORBC ðÞ :
log d OR ORBC
  
+1:96:SE log d OR ORBC
     
Exponentiation of the first and third of the above equations
affords the derivation of point and confidence interval estimates of
ORBC. Specifically, the point estimate of ORBC is given by
d OR ORBC~exp log d OR ORAC
  
{log d OR ORAB
     
while the 95% confidence interval estimate of ORBC has end
points given by
exp log d OR ORBC
  
+1:96:SE log d OR ORBC
        
The 95% confidence interval for ORBC produced by the Bucher
method can be used to test the null hypothesis H0 : ORBC~1
versus Ha : ORBC=1. If this interval precludes the value 1 (which
denotes a null relative effect of B compared to C), we reject the
null hypothesis and conclude that the effect of B is significantly
different from that of C (based on two-sided a=5%). However, if
this interval includes the value 1, we fail to reject the null
hypothesis and conclude that the data do not provide sufficient
evidence in favour of a difference in the effects of the two
treatments.
In practice, the use of random-effects meta-analysis is typi-
cally recommended for deriving both (i) log d OR ORAB
  
and
SE log d OR ORAB
     
and (ii) log d OR ORAC
  
and SE log d OR ORAC
     
.
Methods
Generation of simulated data
Our simulation study was geared at the indirect comparison of
two drugs B and C, which were compared head-to-head against
another drug A, but not against each other. In this study, the direct
comparisons of B versus A and C versus A were performed on the
basis of trials with a binary outcome for each trial participant (i.e.,
participant experienced/did not experience the event of interest).
For this reason, the true relative effects of B versus A and C versus
A were expressed on the odds ratio scale as ORAB and ORAC.
Similarly, the true relative effect of B versus C, which was of
primary interest, was expressed on the odds ratio scale as ORBC.
Using Bucher’s adjusted indirect comparison as a basis for
conducting inferences on ORBC, the simulation study was con-
cerned with answering the following questions:
(I) What is the risk of over-estimation associated with the point
estimation of ORBC?
(II) What are the coverage properties of the confidence interval
estimation method of ORBC?
(III) What are the Type I error properties of the test of
hypotheses Ho : ORBC~1 (null relative effect of C versus B)
versus Ha : ORBC=1 (non-null relative effect of C vs. B)?
(IV) What are the power properties of the test of hypotheses
Ho : ORBC~1 versus Ha : ORBC=1?
The simulation study included six different factors but was not
set up as a full factorial experiment. These factors were: (1) kAB,
the number of trials pertaining to the B versus A comparison; (2)
kAC, the number of trials pertaining to the C versus A comparison;
(3) pA, the true average event rate in the common comparator
group A; (4) ORAB, the true relative effect of B versus A, quantified
as an odds ratio; (5) ORAC, the true relative effect of C versus A,
quantified as an odds ratio; (6) t, the between-study standard
deviation, assumed constant across the comparisons B versus A
and C versus A.
Given these factors, we explored the extent to which the
performance of the indirect inference on ORBC would be
influenced by the size of kAB and kAC, especially in situations
where kAC would either be equal to 1 or larger than 1 but much
smaller than kAB. However, we also considered the influence of
the remaining factors on the indirect inference on ORBC.
Estimating the Power of Indirect Comparisons
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number of combination of values for the factors pA, ORAB and
ORAC, while allowing kAB to take on the values 5, 10, 25 and 100,
kAC to take on the values 1 and 5, and the heterogeneity
parameter t to take the following values: 0.001 (small between-
study heterogeneity), 0.2 (moderate between-study heterogeneity)
and 0.4 (large between-study heterogeneity). The combinations of
values entertained for pA, ORAB and ORAC are listed in Table 1.
Given any such combination of values, the resulting simulation
experiment had a factorial structure with respect to the remaining
factors kAB, kAC and t.
We note the following in connection with the combination of
values reported in Table 1 (See Table 1).
Knowing ORAB and ORAC allows the determination of ORBC,
the true relative effect of B versus C, via the formula
ORBC~exp log ORAC ðÞ {log ORAB ðÞ ðÞ . Using this formula, we
can see that: (i) ORBC~1 for those simulation settings where
ORAB~ORAC~1:4; (ii) ORBC~1:17 for those simulation
settings where ORAB~1:2 and ORAC~1:4 and (iii)
ORBC~1:15 for those simulation settings where ORAB~0:65
and ORAC~0:75.
In addition, if pB and pCdenote the true average event rates in
groups B and C, respectively, we can determine the value of the
former parameter from the values of pA and ORAB and that of the
latter parameter from the values of pA and ORAC:
pB~
ORAB: pA
1{pA
1zORAB: pA
1{pA
and pC~
ORAC: pA
1{pA
1zORAC: pA
1{pA
:
Table 1 shows the resulting values of pB and pC corresponding to
the combinations of values of pA, ORAB and ORAC given in
Table 1 (See Table 1). Based on Table 1, we see that the
simulation settings for which ORAB~ORAC~1:4 have equal true
average event rates in groups B and C and that both of these rates
are higher than the true average event rate in group A. Simulation
settings for which ORAB~1:2 and ORAC~1:4 have different true
average event rates in groups B and C (with the event rate in group
C being slightly higher than that in group B). Both of these rates
are higher than the true average event rate in the common
comparator group A. Simulation settings for which ORAB~0:65
and ORAC~0:75 have a higher average event rate in group C
than in group B, with both of these rates being smaller than the
average event rate in group A.
For each combination of values for the six factors included in
the simulation study, we generated 5,000 sets of kAB trials
comparing B versus A and kAC trials comparing C versus A and
used them as input for conducting indirect inferences on the true
relative effect of B versus C. The data for each of the kAB trials
consisted of counts of events and number of participants in arms A
and B of that trial. Similarly, the data for each of the kAC trials
consisted of counts of events and number of participants in arms A
and C of that trial. For simplicity, we discuss below only the
generation of data from trials comparing B versus A.
Consider the j-th trial comparing B versus A amongst the kAB
trials available for this comparison. The data for this trial were
generated from the following model:
eAj*Binomial nAj,pAj
  
eBj*Binomial nBj,pBj
  
nAj~nBj~
nj
2
with nj*Uniform 20,500 ðÞ
pAj*Uniform pA{pA=2,pAzpA=2 ðÞ
pBj~
pAjexp ln ORAB,j
     
1{pAjzpAjexp ln ORAB,j
     
ln ORAB,j
  
*Normal ln ORAB ðÞ ,t2   
Here, nAj and nBj represent the number of participants in arms A
and B of the j-th trial comparing B versus A. Under the
assumption of equal numbers of participants in both arms
(nAj~nBj), the total number of participants in the two arms was
determined by sampling an integer between 20 and 500
participants.
The number of observed events in group A, eAj, was drawn
from a binomial distribution with parameters nAj and pAj, with pAj
denoting the trial specific event rate in group A. The parameter
pAj was drawn from a uniform distribution with support given by
pA{pA=2,pAzpA=2 ðÞ , where pA is the true average event rate in
group A.
The observed number of events in arm B of the j-th trial
comparing B versus A, eBj, was drawn from a binomial
distribution with parameters nBj and pBj, with pBj denoting the
trial specific event rate in group B. The value of the latter
parameter was derived on the basis of pAj (trial specific event rate
in group A) and ORAB,j (trial-specific true relative effect of B
versus A, expressed as an odds ratio). The natural logarithm of
ORAB,j was sampled from a normal distribution with mean given
by ln ORAB ðÞ and variance given by t2, where t is the between-
study standard deviation. The latter specification is consistent with
assuming that the relative effects of B versus C are different across
trials yet similar enough to be sampled from a common
distribution.
Given the data eAj,nAj,eBj,nBj
  
, j~1,...,kAB, generated for
the kAB trials comparing B versus A, a random-effects meta-
analysis based on the DerSimonian and Laird method was used to
estimate log ORAB ðÞ and its associated standard error.[5] These
estimates – along with similarly obtained estimates of log ORAC ðÞ
and its corresponding standard error - were used as inputs for the
adjusted indirect comparisons method of Bucher.
Table 1. Combination of values for three of the parameters
included in the simulation study, namely pA, ORAB and
ORAC, along with corresponding values of pB and pC.
ORAB ORAC pA pB pC
1.4 1.4 10% 13% 13%
1.4 1.4 30% 37% 37%
1.2 1.4 10% 12% 13%
1.2 1.4 30% 34% 38%
0.65 0.75 40% 30% 33%
doi:10.1371/journal.pone.0016237.t001
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The following measures of performance of the indirect inference
on ORBC were considered in our simulation study:
N Risk of over-estimation;
N Confidence interval coverage;
N Type I error;
N Statistical power.
The risk of overestimation was evaluated only for those
simulation settings where (i) ORAB~1:2 and ORAC~1:4 (hence
ORBC~1:17) or (ii) ORAB~0:65 and ORAC~0:75 (hence
ORBC~1:15). Given a simulation setting, this risk was computed
by recording the proportion of times the indirect estimate of
ORBC exceeded four different thresholds in the 5,000 simula-
tions. The thresholds were selected to represent approximately a
20%, 30%, 50% and 75% increase in the true value of ORBC.
Specifically, when ORBC~1:17, the thresholds were taken to be
1.40, 1.52, 1.75 and 2.05, respectively. When ORBC~1:15, the
thresholds were taken to be 1.38, 1.49, 1.72 and 2.01,
respectively.
The confidence interval coverage was assessed for all simulation
settings. Given a setting, coverage was evaluated by recording the
percentage of simulations out of 5,000 for which the 95%
Table 2. Percentage of simulations producing indirect estimates of ORBC exceeding a given threshold corresponding to the
simulation settings where ORBC~1:17.
pA~10% pA~30%
Threshold for judging
over-estimation of ORBC ORAB~1:2&O R AC~1:4O R AB~1:2&O R AC~1:4
kAB kAC t~0:001 t~0:2 t~0:4 t~0:001 t~0:2 t~0:4
5 1 1.40 36.98 35.98 38.34 28.66 32.70 36.72
1.52 31.00 30.86 34.04 21.04 25.96 31.34
1.75 21.90 22.08 27.00 11.44 16.44 23.14
2.05 14.38 14.56 19.98 6.04 9.36 15.40
10 1 1.40 35.30 36.56 37.58 27.92 31.58 34.88
1.52 29.58 30.30 32.90 19.84 24.22 29.88
1.75 21.54 22.66 26.22 10.58 14.74 22.20
2.05 14.52 15.14 18.80 5.72 7.96 15.32
25 1 1.40 34.38 36.22 37.92 26.06 30.86 36.18
1.52 27.72 30.44 33.18 18.18 23.94 30.84
1.75 19.26 21.70 25.28 10.60 14.40 21.78
2.05 12.56 14.46 18.10 5.40 7.58 13.96
100 1 1.40 34.12 35.16 37.18 26.02 31.24 36.70
1.52 27.90 29.62 32.50 19.22 23.82 31.06
1.75 19.94 21.12 25.12 10.16 14.30 22.76
2.05 12.90 13.74 18.1 5.18 8.04 14.42
5 5 1.40 24.68 26.18 30.20 15.30 19.74 28.20
1.52 16.34 18.08 23.24 7.16 11.26 20.52
1.75 6.26 8.54 13.92 1.44 3.58 10.32
2.05 2.12 3.04 7.14 0.18 0.68 4.34
10 5 1.40 22.00 22.88 28.78 11.36 16.56 24.98
1.52 12.38 14.54 20.66 4.22 8.22 16.86
1.75 4.24 5.66 10.28 0.54 2.16 6.78
2.05 0.88 1.18 3.84 0.00 0.26 1.90
25 5 1.40 18.52 19.56 25.16 13.46 13.46 22.88
1.52 9.58 11.24 17.46 5.78 5.78 14.28
1.75 2.34 3.50 7.98 0.84 0.84 4.96
2.05 0.30 0.62 2.8 0.08 0.08 1.40
100 5 1.40 17.16 18.40 23.58 6.62 8.76 20.66
1.52 8.90 9.84 14.78 1.80 2.56 11.92
1.75 2.22 2.36 5.92 0.12 0.06 4.20
2.05 0.34 0.36 1.62 0.00 0.06 0.66
Four different thresholds were considered for each simulation setting: 1.40, 1.52, 1.75 and 2.05. These thresholds were chosen to represent an approximate increase of
20%, 30%, 50% and 75% in the value of ORBC. Reported percentages quantify the degree to which Bucher’s method over-estimatesORBC. (Note: The true average
event rate in group A was either 10% or 30%).
doi:10.1371/journal.pone.0016237.t002
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ORBCcorresponding to that setting.
The type I error of the test ofHo : ORBC~1 against
Ha : ORBC=1 was evaluated only for those simulation settings
with ORAB~ORAC~1:4 for which the null hypothesis was true
(i.e., ORBC~1). For each such setting, Type I error was assessed
by tracking the percentage of simulations out of 5,000 which
produced 95% confidence intervals for ORBC that excluded the
value 1.
The statistical power of the test of Ho : ORBC~1 against
Ha : ORBC=1 was computed only for those simulation settings
with ORAB~1:2 and ORAC~1:4 or ORAB~0:65 and
ORAC~0:75, for which the null hypothesis was false. For each
such setting, power was expressed as the percentage of simulations
out of 5,000 which produced 95% confidence intervals for ORBC
that excluded the value 1.
Software Implementation
All simulations were performed using the freely available
software package R 2.11.0.[6] All random-effects meta-analyses
pertaining to the direct comparisons of B against A and C against
A were conducted using the R package metafor (version 1.1-0).
Table 3. Percentage of simulations producing indirect estimates of ORBC exceeding a given threshold corresponding to the
simulation settings where ORBC~1:15 (or, equivalently, ORAB~0:65 & ORAC~0:75).
pA~40%
Threshold for judging over-estimation of ORBC ORAB~0:65 & ORAC~0:75
kAB kAC t~0:001 t~0:2 t~0:4
5 1 1.38 28.48 30.98 37.4
1.49 21.12 24.92 32.04
1.72 11.54 15.68 23.78
2.01 5.54 8.78 15.92
10 1 1.38 26.46 31.56 34.72
1.49 19.24 25.12 29.64
1.72 10.26 14.52 21.86
2.01 5.44 7.46 14.38
25 1 1.38 27.26 30.00 35.78
1.49 20.12 23.58 30.52
1.72 9.98 13.66 22.20
2.01 5.36 7.10 14.34
100 1 1.38 26.12 30.00 35.76
1.49 19.46 23.84 30.18
1.72 9.52 14.00 21.18
2.01 4.92 8.22 13.46
5 5 1.38 15.3 20.72 28.64
1.49 7.88 12.50 21.06
1.72 1.24 3.24 11.18
2.01 0.10 0.66 4.64
10 5 1.38 11.46 17.42 25.04
1.49 4.62 9.28 17.46
1.72 0.44 2.20 7.70
2.01 0.04 0.32 2.16
25 5 1.38 8.68 14.64 22.76
1.49 2.58 7.04 14.44
1.72 0.10 1.18 4.82
2.01 0.00 0.06 1.04
100 5 1.38 16.84 12.14 21.16
1.49 2.26 5.02 12.94
1.72 0.02 0.84 4.42
2.01 0.00 0.04 0.88
Four different thresholds were considered for each simulation setting: 1.38, 1.49, 1.72 and 2.01. These thresholds were chosen to represent an approximate increase of
20%, 30%, 50% and 75% in the value of ORBC. Reported percentages quantify the degree to which Bucher’s method over-estimates ORBC. (Note: The true average
event rate in group A was 40%).
doi:10.1371/journal.pone.0016237.t003
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Risk of over-estimation
Table 2 presents the risk of over-estimation of ORBC for
simulation settings where ORAB~1:2 and ORAC~1:4 while
Table 3 presents the same quantity for those settings where
ORAB~0:65 and ORAC~0:75.
When kAC is 1,the true relative effect ORBC is often considerably
overestimated. When kAC is 5, the overestimation is both less
frequent and pronounced. For both of these values of kAC, the more
trials are available for the direct comparison of B versus A (i.e., the
larger kAB), the smaller the risk of overestimation becomes.
Coverage
Tables 4, 5 and 6 present the empirical coverage of the 95%
confidence interval estimation method of Bucher for ORBC for
simulation settings where ORAB~ORAC~1:4, ORAB~1:2 and
ORAC~1:4, and ORAB~0:65 and ORAC~0:75, respectively.
(The nominal coverage is 95%.)
For the all of these settings, the Bucher confidence interval
estimation method generally reports empirical coverage values
below the nominal coverage when the between-study heterogene-
ity is moderate or large (i.e., t~0:2 or 0:4) - a phenomenon
referred to as undercoverage. As anticipated, the undercoverage
tends to be more pronounced when kAC equals 1 than when kAC
equals 5. Undercoverage could either be due to bias in the
estimates of ORBC or due to underestimation of SE ORBC ðÞ (which
would cause the confidence interval to be artificially narrow).
When the between-study heterogeneity is small (i.e., t~0:001),
the estimated coverage of is generally either greater or slightly
smaller than the nominal coverage, suggesting that the method
produces conservative or valid confidence intervals. In particular,
coverage exceeding the nominal level indicates that the Bucher
method produces overly wide confidence intervals in this scenario.
Increasing the value of kAC from 1 to 5 while keeping kAB fixed
has a minimal impact on the empirical coverage of the method.
When the between-study heterogeneity is moderate (i.e., t~0:2)
and especially large (i.e., t~0:4), the estimated coverage is
generally smaller than the nominal level. Increasing the value of
kAC from 1 to 5 while keeping kAB fixed results in coverages closer
to the nominal level, albeit still off by as much as 5%.
Type I Error
Table 7 displays the estimated Type I error associated with the
test of H0 : ORBC~1 versus H0 : ORBC=1 for those simulation
settings with ORAB~ORAC~1:4. (The nominal Type I error is
5%.) For these settings, the estimated Type I error falls below the
nominal Type I error when the between-study heterogeneity is
small (i.e., t~0:001) but exceeds the nominal Type I error when
the between-study heterogeneity is moderate or large (i.e.,
t~0:2or 0:4). For fixed values of kAB and kAC, the levels of the
estimated Type I error increases as the between-study heteroge-
neity increases. These findings hold for most values of kAB and
regardless of whetherkAC equals 1 or 5.
Table 4. Coverage of the 95% confidence interval estimation
method of Bucher for ORBC.
kAB kAC pA~10% pA~30%
ORAB~ORAC~1:4O R AB~ORAC~1:4
t~0:001 t~0:2 t~0:4 t~0:001 t~0:2 t~0:4
5 1 96.02 94.28 87.90 95.44 89.94 81.10
10 1 96.06 94.00 87.78 95.68 90.38 79.52
25 1 96.20 93.70 86.98 95.42 89.70 77.04
100 1 96.18 93.40 85.84 95.12 88.88 76.24
5 5 95.24 93.20 91.70 95.02 92.86 91.22
10 5 96.00 95.22 92.54 95.90 93.96 92.26
25 5 96.72 95.22 92.50 96.90 93.28 91.32
100 5 96.68 94.80 92.50 96.88 93.44 90.44
For each simulation setting, coverage was assessed by tracking the percentage
of simulations producing confidence intervals for ORBC that captured the true
value of ORBC. For settings where ORAB~ORAC~1:4, the true value of
ORBC was 1. (Note: The true average event rate in group A was either 10% or
30%).
doi:10.1371/journal.pone.0016237.t004
Table 5. Coverage of the 95% confidence interval estimation
method of Bucher for ORBC.
kAB kAC pA~10% pA~30%
ORAB~1:2&O R AC~1:4O R AB~1:2&O R AC~1:4
t~0:001 t~0:2 t~0:4 t~0:001 t~0:2 t~0:4
5 1 95.86 92.44 88.12 95.34 90.74 81.80
10 1 96.20 93.82 86.80 95.42 90.14 78.44
25 1 96.68 93.26 86.12 94.92 90.32 77.20
100 1 95.80 92.84 86.06 95.50 88.58 74.16
5 5 95.08 93.74 91.74 95.08 92.58 91.36
10 5 96.28 95.04 92.70 96.00 93.76 92.12
25 5 96.80 94.60 92.24 96.06 93.62 90.66
100 5 97.04 95.28 90.88 97.30 93.00 89.50
For each simulation setting, coverage was assessed by tracking the percentage
of simulations producing confidence intervals for ORBC that captured the true
value of ORBC. For settings where ORAB~1:2 & ORAC~1:4, the true value of
ORBC was 1:17. (Note: The true average event rate in group A was either 10%
or 30%).
doi:10.1371/journal.pone.0016237.t005
Table 6. Coverage of the 95% confidence interval estimation
method of Bucher for ORBC.
kAB kAC pA~40%
ORAB~0:65 & ORAC~0:75
t~0:001 t~0:2 t~0:4
5 1 94.94 89.12 80.34
10 1 94.70 89.12 78.58
25 1 95.72 89.14 75.82
100 1 95.30 87.78 75.66
5 5 95.28 93.00 91.10
10 5 95.92 93.22 91.64
25 5 96.70 93.02 90.72
100 5 96.72 93.00 89.70
For each simulation setting, coverage was assessed by tracking the percentage
of simulations producing confidence intervals for ORBC that captured the true
value of ORBC. For settings where ORAB~0:65 & ORAC~0:75, the true value
of ORBC was 1.15. (Note: The true average event rate for group A was 40%).
doi:10.1371/journal.pone.0016237.t006
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Tables 8 and 9 show the estimated power of the test of
H0 : ORBC~1 versus H0 : ORBC=1 for those simulation settings
with either ORAB~1:2 and ORAC~1:4,o rORAB~0:65 and
ORAC~0:75. The results in these two tables show that this test is
profoundly underpowered across both types of simulation settings.
As expected, when kAB is kept fixed, increasing the value of kAC
from 1 to 5 does result in an increase in the level of power, with the
magnitude of this increase depending on the value of the between-
study standard deviation t. Similarly, when kAC is kept fixed,
increasing the value of kAB results in an increase in the level of
power. Nevertheless, these increases in power are not large enough
to overcome the issue of lack of power.
Discussion
Our study demonstrates that adjusted indirect comparisons are
severely affected by the power and fragility of the data in the
contributing comparisons. Given the growing acceptance and
increased use of indirect comparisons in health-care decision-
making, there is a need for caution when determining the strength
of evidence from indirect comparisons. In particular, health-care
decision makers should carefully assess the strength of evidence
within each comparison (e.g., A vs B and A vs C) to grasp the
reliability of the produced indirect point estimate and confidence
interval.[7]
There are strengths and limitations to consider when interpret-
ing our simulation study. Strengths of this study include the use of
clinically reasonable assumptions about treatment effects and the
simulation of varying scenarios of clinical importance versus
statistical importance. Further, we explored inferential properties
for the simplest form of indirect comparison (A vs B and A vs C).
Such comparisons are present in multitude in more complex
indirect comparisons and multiple treatment comparisons (MTC).
To a considerable extent, our results may therefore extrapolate
beyond the simulated scenarios as the underlying statistical
assumptions used in MTC are similar.[8,9] The limitations of
our study include the overarching issue that we used simulations
rather than real data for our analysis. We investigated the impact
of the number of direct comparison trials on various statistical
properties of an indirect comparison while allowing the sample
size of each direct trial to follow a uniform distribution from 20 to
500. This setup ensured that our simulation scenarios are
representative of real-world meta-analytic situations, where trials
pertaining to a direct comparison typically vary in their sample
sizes. However, our ability to reproduce such situations came with
a price: we were unable to assess the effect of the trial sample size
on the power of an indirect comparison, due to its confounding
with the other factors examined in our simulation study, such as
heterogeneity. Furthermore, we assessed the risk of overestimation,
confidence interval coverage and statistical power of an indirect
comparison involving two treatments, but we did not examine
these statistical features for the direct comparison involving the
same two treatments. One reason for this is that, in practice,
Table 7. Type I error associated with the test of the
hypotheses H0 : ORBC~1 versus Ha : ORBC=1.
pA~10% pA~30%
ORAB~ORAC~1:4O R AB~ORAC~1:4
kAB kAC t~0:001 t~0:2 t~0:4 t~0:001 t~0:2 t~0:4
5 1 3.98 5.72 12.10 4.56 10.06 18.90
10 1 3.94 6.00 12.22 4.32 9.62 20.48
25 1 3.80 6.30 13.02 4.58 10.30 22.96
100 1 3.82 6.60 14.16 4.88 11.12 23.76
5 5 4.76 6.80 8.30 4.98 7.14 8.78
10 5 4.00 7.78 7.46 4.10 6.04 7.74
25 5 3.28 4.78 7.50 3.10 6.72 8.68
100 5 3.32 5.20 7.50 3.12 6.06 9.56
For each simulation setting where ORBC~1 (or, equivalently,
ORAB~ORAC~1:4), Type I error was assessed by tracking the percentage of
simulations that produced 95% confidence intervals that excluded the value 1.
(Note: The true average event rate in group A was either 10% or 30%).
doi:10.1371/journal.pone.0016237.t007
Table 8. Power associated with the test of the hypotheses
H0 : ORBC~1 versus Ha : ORBC=1.
pA~10% pA~30%
ORAB~1:2&O R AC~1:4O R AB~1:2&O R AC~1:4
kAB kAC t~0:001 t~0:2 t~0:4 t~0:001 t~0:2 t~0:4
5 1 6.06 7.56 13.04 7.06 12.16 19.60
10 1 5.60 7.58 13.70 8.18 12.70 22.38
25 1 4.88 8.12 14.94 8.50 13.46 24.62
100 1 5.60 8.18 15.54 7.94 14.42 27.14
5 5 8.38 9.54 9.76 13.04 12.32 11.20
10 5 8.76 9.04 10.22 14.08 12.94 11.12
25 5 9.38 9.82 11.54 15.58 15.36 14.64
100 5 10.42 10.76 12.98 16.60 17.74 14.84
For each simulation setting where ORBC~1:17 (or, equivalently,
ORAB~1:2 & ORAC~1:4), power was assessed by tracking the percentage of
simulations that produced 95% confidence intervals for ORBC that excluded
the value 1. (Note: The true average event rate in group A was either 10% or
30%).
doi:10.1371/journal.pone.0016237.t008
Table 9. Power associated with the test of the hypotheses
H0 : ORBC~1 versus Ha : ORBC=1.
pA~40%
ORAB~0:65 & ORAC~0:75
kAB kAC t~0:001 t~0:2 t~0:4
5 1 7.80 12.96 21.16
10 1 7.42 13.00 22.92
25 1 8.08 13.06 24.76
100 1 8.36 15.02 26.18
5 5 12.42 12.12 11.40
10 5 13.14 12.98 12.40
25 5 14.18 14.86 13.68
100 5 16.84 15.96 15.04
For each simulation setting where ORBC~1:15 (or, equivalently,
ORAB~0:65 & ORAC~0:75), power was assessed by tracking the percentage
of simulations that produced 95% confidence intervals for ORBC that excluded
the value 1. (Note: The true average event rate in group A was 40%).
doi:10.1371/journal.pone.0016237.t009
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comparisons cannot be performed due to a lack of direct evidence.
While it is possible to expand our simulation study to include a
comparison of the statistical properties of direct and indirect
comparison concerning the same treatments, we chose not to
pursue this here in an effort to preserve the simplicity of our
findings and interpretations. We hope to address this issue in a
future paper. We used the DerSimonian-Laird random-effects
model which makes use of the DerSimonian-Laird estimator to
estimate the between-study variation. This estimator has been
known to underestimate the between-study variance.[10 11,
12]Thus, the undercoverage and inflation of type I error we
detected in simulation scenarios with moderate or large hetero-
geneity may in part be caused by properties of this estimator rather
than properties of the Bucher adjusted indirect comparison
method. [1]
The use of indirect comparisons and MTC analyses is growing
in popularity in both journal publications and by health
technology assessments.[2] The criticisms of both approaches is
that it is not obvious where biases or errors may arise from,
including issues of individual trial bias, trial-level differences across
comparisons, and problems in the conduct of the indirect
model.[13] Authors and readers appear to have difficulty
interpreting the quality of indirect comparison meta-analysis and
tools for critical appraisal do not yet exist.[14] Our study
demonstrates that caution is warranted, especially in situations
where low numbers of trials are included in any treatment arm.
Insights from empirical studies are crucially needed to further
inform this issue. Further, we hope investigate the fragility and
power associated with point estimation and hypothesis testing in
MTC in a near future.
In conclusion, indirect comparisons with 1 or 5 trials in one of
the indirect comparison arms are consistently underpowered
(power ,20%), regardless of the number of trials in the other
indirect comparison arm. Results from indirect comparisons may
especially become unreliable with the heterogeneity is moderate or
large. Authors and readers of indirect comparisons should exercise
caution and scepticism when interpreting results from indirect
comparisons.
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